Generic Name |
Trametinib + Palbociclib | |
---|---|---|
IND |
||
Brand Name (US) |
||
Manufacturer |
GlaxoSmithKline | |
Drug Type |
||
Delivery |
Oral | |
Approval Status |
||
Indications |
||
Overall Strategy |
Oncogenic Signal Path Based | |
Strategy |
Block related tumor signal paths | |
Drug Category |
MEK Inhibitor + CDK4/6 Inhibitor |